CEFTRIAXONE injection, powder, for solution

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

CEFTRIAXONE SODIUM (UNII: 023Z5BR09K) (CEFTRIAXONE - UNII:75J73V1629)

Commercializzato da:

Fresenius Kabi USA, LLC

INN (Nome Internazionale):

CEFTRIAXONE SODIUM

Composizione:

CEFTRIAXONE SODIUM 500 mg

Via di somministrazione:

INTRAVENOUS

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections

Dettagli prodotto:

Ceftriaxone for Injection, USP is supplied as a sterile crystalline powder in glass vials. The following packages are available: NOTE: Ceftriaxone for Injection, USP sterile powder should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature], and protected from light. The container closure is not made with natural rubber latex.

Stato dell'autorizzazione:

Abbreviated New Drug Application

Scheda tecnica

CEFTRIAXONE - CEFTRIAXONE INJECTION, POWDER, FOR SOLUTION
FRESENIUS KABI USA, LLC
----------
CEFTRIAXONE FOR INJECTION, USP
RX ONLY
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
Ceftriaxone for Injection and other antibacterial drugs, Ceftriaxone
for Injection should
be used only to treat or prevent infections that are proven or
strongly suspected to be
caused by bacteria.
DESCRIPTION:
Ceftriaxone for Injection, USP is a sterile, semisynthetic,
broad-spectrum cephalosporin
antibiotic for intravenous or intramuscular administration.
Ceftriaxone sodium is
(6_R_,7_R_)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-
3-[[(1,2,5,6-tetrahydro-2-
methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid, 7 -(_Z_)-(_O_-methyloxime), disodium salt,
sesquaterhydrate.
The structural formula of ceftriaxone sodium is:
C
H N NA O S •3.5H O M.W. 661.60
Ceftriaxone for Injection, USP is a white to yellowish-orange
crystalline powder which is
readily soluble in water, sparingly soluble in methanol and very
slightly soluble in ethanol.
The pH of a 1% aqueous solution is approximately 6.7. The color of
Ceftriaxone for
Injection, USP solutions ranges from light yellow to amber, depending
on the length of
storage, concentration and diluent used.
Ceftriaxone for Injection, USP contains approximately 83 mg (3.6 mEq)
of sodium per
gram of ceftriaxone activity.
CLINICAL PHARMACOLOGY:
Average plasma concentrations of ceftriaxone following a single
30-minute intravenous
(IV) infusion of a 0.5, 1 or 2 g dose and intramuscular (IM)
administration of a single 0.5
(250 mg/mL or 350 mg/mL concentrations) or 1 g dose in healthy
subjects are
presented in Table 1.
TABLE 1. CEFTRIAXONE PLASMA CONCENTRATIONS AFTER SINGLE DOSE
ADMINISTRATION
2
18
16
8
2
7 3
2
Dose/Route
Average Plasma Concentrations (mcg/mL)
0.5 hr
1 hr
2 hr
4 hr
6 hr
8 hr
12 hr
16 hr
24 hr
0.5 g IV*
82
59
48
37
29
23
15
10
5
0.5 g IM
250 mg/mL
22
33
38
35
30
26
16
ND
5
0.5 g IM
350 mg/mL
20
32
38
34